We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Proteomic Methods Diagnose Pancreatic Cancer

By LabMedica International staff writers
Posted on 08 Apr 2014
A method has been developed that identifies pancreatic cancer's visible precursors with 97% certainty, and is expected to aid in the early discovery of the cancer as well as minimize the risk of unnecessary surgery. More...


The poor prognosis for pancreatic cancer, is due to the fact that the tumors often develop unnoticed, and rarely causes symptoms until they have spread to other organs, however fluid-filled compartments in the pancreas, called cysts, may be precursors of the cancer.

Scientists at the Sahlgrenska University Hospital (Gothenburg, Sweden) evaluated whether cyst fluid mucin expression could predict malignant potential and/or transformation in pancreatic cystic lesions (PCLs). A proteomic method was devised and prospectively evaluated in consecutive patients referred to a tertiary center for endoscopic ultrasound-guided aspiration of cystic lesions from May 2007 through November 2008 (discovery cohort) and from December 2008 through October 2012 (validation cohort).

Cytology and cyst fluid carcinoembryonic antigen (CEA; premalignancy greater than 192 ng/mL, malignancy greater than 1,000 ng/mL) were routinely analyzed. Samples were further processed as follows: one-dimensional gel electrophoresis, excision of high-mass areas, tryptic digestion and nanoliquid chromatography–tandem mass spectrometry, with peptide identification. Peptides were separated on a reversed column coupled to a hybrid linear ion trap-Fourier transform ion cyclotron resonance mass spectrometry instrument equipped with a 7-tesla magnet (LTQ-FT; Thermo Electron; Bremen, Germany).

Proteomic mucin profiling proved statistically significantly more accurate at 97.5%; than cytology at 71.4%, and cyst fluid CEA at 78.0% in identifying the 37/79 (46.8%) lesions with malignant potential, either premalignant or malignant tumors. The accuracy of proteomics was nearly identical, 96.6% versus 98.0%, between the 29 patients in the discovery and 50 patients in the validation cohorts. Furthermore, mucin profiling predicted malignant transformation, present in 16/29 lesions with available histology, with 89.7% accuracy.

Karolina Sjöberg Jabbar, MD, the corresponding author of the study said, “This is an exceptionally good result for a diagnostic test, and we are very hopeful that the method will enable more instances of early discovery of pancreatic cancer, at a stage when the cancer can be treated or prevented. This approach may also minimize the risk of unnecessary operations on nonmalignant cysts.” The study was published in the March 2014 issue of the Journal of the National Cancer Institute.

Related Links:
Sahlgrenska University Hospital  
Thermo Electron 


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.